# Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

> **NCT01746979** · PHASE3 · COMPLETED · sponsor: **ImmunoGenesis** · enrollment: 693 (actual)

## Conditions studied

- Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** TH-302
- **DRUG:** Gemcitabine
- **DRUG:** Placebo (5 percent dextrose - D5W)

## Key facts

- **NCT ID:** NCT01746979
- **Lead sponsor:** ImmunoGenesis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-05
- **Target enrollment:** 693 (ACTUAL)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746979, "Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01746979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*